Complete report $4,500. DataPack (test volumes, sales forecasts, supplier shares) $2,900.
This new 278-page report from Venture Planning Group provides analysis of the US sexually-transmitted disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
The report presents detailed analysis of the STD market in the US, Current scientific views on epidemiology and etiology are presented for Chancroid, Chlamydia, Gonorrhea, Herpes, HPV, and Syphilis. The report provides test volume and sales forecasts and market segment, including:
- Commercial/Private Labs
- Physician Offices
- Public Health Labs
In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of STD diagnostic products, by test. Also, the report:
- Examines market applications of Molecular Diagnostics,
Monoclonal Antibodies, Immunoassays, IT and other emerging technologies;
- Reviews features and operating characteristics of major analyzers used
for STD testing;
- Profiles key suppliers and potential market entrants developing innovative
technologies and products; and
- Analyzes emerging opportunities, alternative market penetration strategies,
market entry barriers/risks, and strategic planning issues.
The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products in the US.
In addition to primary sources of information, a comprehensive review of
the most recent technical and business publications, manufacturer product
and financial literature, as well as Venture Planning Groups proprietary data files was conducted.
Contains 278 pages and 18 tables